Next Article in Journal
Adsorption of Helium and Hydrogen on Triphenylene and 1,3,5-Triphenylbenzene
Previous Article in Journal
Proximate, Elemental, and Functional Properties of Novel Solid Dispersions of Moringa oleifera Leaf Powder
Previous Article in Special Issue
64CuCl2 PET Imaging of 4T1-Related Allograft of Triple-Negative Breast Cancer in Mice
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 27
Issue 15
10.3390/molecules27154936
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer

by
Chaninart Sakulpisuti
,
Putthiporn Charoenphun
and
Wichana Chamroonrat
*
Division of Nuclear Medicine, Department of Diagnostic and Therapeutic Radiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
*
Author to whom correspondence should be addressed.
Molecules 2022, 27(15), 4936; https://doi.org/10.3390/molecules27154936
Submission received: 29 June 2022 / Revised: 1 August 2022 / Accepted: 1 August 2022 / Published: 3 August 2022
(This article belongs to the Special Issue Radiopharmaceuticals for PET Imaging - Issue B)
Browse Figures
Review Reports Versions Notes

Abstract

:
Differentiated thyroid cancer (DTC), arising from thyroid follicular epithelial cells, is the most common type of thyroid cancer. Despite the well-known utilization of radioiodine treatment in DTC, i.e., iodine-131, radioiodine imaging in DTC is typically performed with iodine-123 and iodine-131, with the current hybrid scanner performing single photon emission tomography/computed tomography (SPECT/CT). Positron emission tomography/computed tomography (PET/CT) provides superior visualization and quantification of functions at the molecular level; thus, lesion assessment can be improved compared to that of SPECT/CT. Various types of cancer, including radioiodine-refractory DTC, can be detected by 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG), the most well-known and widely used PET radiopharmaceutical. Several other PET radiopharmaceuticals have been developed, although some are limited in availability despite their potential clinical utilizations. This article aims to summarize PET radiopharmaceuticals in DTC, focusing on molecular pathways and applications.

1. Introduction

Differentiated thyroid cancer (DTC), arising from thyroid follicular epithelial cells, constitutes the majority of thyroid malignancies (>90%) [1]. This category consists of papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), and oncocytic carcinoma [2,3]. The incidence rates of DTC differ among countries; iodine inadequacy and access to healthcare are the two largest causes. In the United States, the incidence has progressively increased over the last decade, with an overall age-adjusted annual rate of 15/100,000 in 2015, and this resulted from the majority rise in incidental PTC [2]. Although the estimated 5-year disease-specific survival in PTC and FTC is excellent in patients with localized (99.9%) and regional (98.3%) disease, it is markedly lower in patients with distant metastasis (53.3%) [4]. Therefore, imaging plays an important role in diagnosis, treatment planning, and monitoring.
Ultrasonography, computed tomography (CT), and magnetic resonance imaging are anatomical imaging modalities recommended for the preoperative evaluation of the primary tumor and locoregional and distant metastases, and in searching for structural residual or recurrent disease in patients with high serum thyroglobulin (Tg) [1].
Nuclear medicine imaging, single photon emission tomography (SPECT), and positron emission tomography (PET) provide the visualization and quantification of functions at the cellular or molecular level. In combination with CT, lesion localization can be further defined [5]. For SPECT imaging, iodine-123 and iodine-131 (131I) are well-known types of radioiodine (RAI) used for detecting metastatic DTC after thyroidectomy because of the expression of the sodium-iodine symporter (NIS) [6]. PET is considered to have a better resolution and sensitivity compared to SPECT [5], and several PET radiopharmaceuticals are currently accessible for clinical use.
The aim of this review article is to summarize PET radiopharmaceuticals in DTC, focusing on molecular pathways and applications.

2. Iodine-Related PET Radiopharmaceuticals

Iodine-124 (124I)

124I is a positron-emitting, long-lived PET radionuclide and has a physical half-life of 4.2 days [7]. It decays dual high-energy positrons (1532 keV (11%) and 2135 keV (11%)) and performs electron capture with gamma emissions of 511 keV (46 %), 603 keV (61 %), and 1691 keV (11 %) [7,8]. Although the reduced PET imaging resolution has been a concern due to 124I’s physical properties, namely (1) high energy positron emission with a long positron range before annihilation with an electron occurs, and (2) a high fraction of nonpositron decays, 124I PET imaging is feasible with current reconstruction algorithms [8,9].
124I, similarly to other RAI isotopes, is trapped by NIS in residual thyroid tissue or tumor in the thyroidectomy bed and metastatic lesion. Thyroid-stimulating hormone (TSH) is used to increase NIS expression [10]. Therefore, a low dose of 124I is orally administered after appropriate thyroid-stimulating hormone (TSH) stimulation, either by thyroid hormone withdrawal or two consecutive days of intramuscular injection of recombinant human TSH (rhTSH), along with a low-iodine diet. Subsequently, the 124I PET scan can be performed up to 96 h after tracer administration [11]. Wu et al. studied the optimal time for 124I PET/CT scan and suggested that dual-time-point imaging was superior to single-time-point imaging, and dual time points at 48 + 72 h or 48 + 96 h yielded the highest lesion detection rate [12].
Several studies performed 124I PET(/CT) for postoperative staging, pre-therapeutic dosimetry, follow-up treatment response, and assessment of persistent or recurrent disease [13,14,15,16,17,18,19,20,21,22]. Ruhlmann et al. found excellent agreement between pre-therapeutic 124I PET and post-therapeutic 131I whole-body scan (WBS) and SPECT/CT in detecting iodine-avid metastatic DTC [13], and Nostrand et al. demonstrated that 124I PET identified additional iodine-avid residual thyroid or metastases that were not seen with 131I [14]. A meta-analysis of five studies in DTC patients reported that 124I PET/CT was a highly sensitive imaging modality for detecting RAI-avid lesions amenable to RAI therapy (pooled sensitivity = 94.2%). It also detected some new lesions that were not visualized on the post-therapeutic 131I scan [23]. However, Khorjekar et al. found that negative 124I PET imaging had low predictive value for a negative post-therapeutic 131I scan and should not be used to exclude the option of blind 131I therapy in patients who are suspected to have metastatic DTC [15].

3. Non-Iodine-Related PET Radiopharmaceuticals

3.1. 18F Tetrafluoroborate ([18F]TFB)

Fluorine-18 (18F) is a positron-emitting radionuclide produced by a cyclotron. It has a high positron decay ratio (97%), relatively short half-life (109.7 min), and low positron energy (maximum 635 KeV) [24]. The positron energy results in a short diffusion range (<2.4 mm) that favorably increases the resolution limits of the PET images [24].
Apart from I−, several anions, such as TcO4−, ReO4−, ClO4−, and Br−, can be transported via NIS. [18F]TFB is a PET isotope labeling with borate anion, used for thyroid and NIS imaging [25,26]. The radiolabeling with fluoride provides a better imaging resolution and a lower effective dose as compared to 124I imaging because of its properties [9,25]. It is pharmacologically and radiobiologically safe in humans [25]. The detection rate of local recurrent or metastatic DTC by [18F]TFB PET/CT is significantly higher than that of 131I diagnostic WBS and SPECT/CT [27]. A pilot study reported that PET/CT imaging with [18F]TFB was not inferior to 124I in newly diagnosed DTC after total thyroidectomy, and the agreement rate between the two radiopharmaceuticals was 91% [28].

3.2. 2-[18F]Fluoro-2-deoxy-D-glucose ([18F]FDG)

[18F]FDG is considered the most well-known radiopharmaceutical in oncologic imaging, commonly synthesized by a nucleophilic substitution reaction [29]. 18F replaces the hydroxyl group on the 2-carbon of a glucose molecule [29]. As a glucose analog, it is transported into the cells via glucose transporter (GLUT) protein and phosphorylated into [18F]FDG-6-phosphate by hexokinase. However, unlike glucose, [18F]FDG-6-phosphate is not further metabolized and consequently trapped within the cells. Therefore, it can be detected by PET imaging [30,31]. Because malignant cells upregulate membrane GLUT proteins (notably GLUT1 and GLUT3) and increase enzymes along the glycolytic pathway, [18F]FDG is more accumulated in cancer cells relative to normal cells [30].
The “flip-flop” phenomenon between iodine and [18F]FDG uptake has been described in DTC. Generally, well-DTC has high iodine and low [18F]FDG uptake (Figure 1). In contrast, poorly DTC and anaplastic thyroid cancer have low iodine and high FDG uptake [32,33]. When DTC becomes dedifferentiated, losing the typical morphology and genetic profile of good differentiation, it decreases the iodine concentration, upregulates GLUT, increases [18F]FDG uptake, and behaves more aggressively [33,34], as shown in Figure 2.
According to the American Thyroid Association (ATA) guidelines of 2015 for thyroid cancer, [18F]FDG PET imaging should be considered in high-risk DTC patients with elevated serum Tg (generally > 10 ng/mL) and negative RAI imaging [1]. Similarly, the Society of Nuclear Medicine and Molecular Imaging and the European Association of Nuclear Medicine recommend performing [18F]FDG PET/CT imaging, ultrasound of the neck, and/or CT of the neck, chest, abdomen, and pelvis in DTC patients with elevated Tg and negative diagnostic RAI WBS [10]. There have been controversial reports about the need for TSH stimulation in early [18F]FDG PET/CT imaging [35]. A recent meta-analysis reported that the diagnostic performance of PET/CT with TSH stimulation may not be superior to PET/CT without TSH stimulation; however, further well-designed studies evaluating the actual patients’ additional oncological benefit after performing TSH stimulation are necessary [36].
In patients with negative RAI scan and elevated serum Tg, [18F]FDG PET/CT had high diagnosis accuracy for detecting recurrent and/or metastatic DTC [36,37]. Caetano et al. reported that the combined sensitivity, specificity, and overall accuracy of [18F]FDG PET/CT were 93%, 81%, and 93%, respectively [37], while Qichang et al. found that in a patient-based analysis, the pooled sensitivity, specificity, and receiver operating characteristics curve were 86%, 84%, and 95%, respectively [36]. Vrachimis et al. demonstrated that in patients with DTC and with suspected or known dedifferentiation, [18F]FDG PET/MRI was inferior to low-dose [18F]FDG PET/CT for the evaluation of pulmonary status, but it was equal to contrast-enhanced neck [18F]FDG PET/CT for the evaluation of cervical status. Therefore, the authors suggested obtaining [18F]FDG PET/MRI combined with a low-dose CT scan of the chest instead of a high-quality, high-energy, contrast-enhanced CT [38]. In this clinical setting, PET/CT parameters alone or combined with other prognostic factors can help to identify patients with poor outcomes [39]. Albano et al. found that the only independent prognostic factors for overall survival were total metabolic tumor volume and total lesion glycolysis of all lesions with increased [18F]FDG uptake [40].
Elevated thyroglobulin antibody might indicate recurrent and/or metastatic disease and could be used as an alternative tumor marker for DTC [41]. Several studies showed that [18F]FDG PET/CT may be a useful imaging modality to investigate patients with a negative RAI scan and positive/elevated thyroglobulin antibody [42,43,44].
An increase in [18F]FDG PET/CT imaging leads to increase in thyroid incidentalomas (Figure 3), defined by focal or diffuse [18F]FDG uptake in the thyroid gland [9]. A systematic review and meta-analysis of 50 studies reported that the prevalence of [18F]FDG-avid focal thyroid incidentaloma was 2.2%, and the risk of malignancy was 30.8%, most of which were PTC [45]. The 2015 ATA guidelines recommended performing fine-needle aspiration of a focal [18F]FDG-avid thyroid incidentaloma, sonographically confirmed by a thyroid nodule ≥ 1 cm in size [1]. In contrast, diffuse [18F]FDG uptake in the thyroid gland favors benign etiologies.
Piccardo et al. studied the association between [18F]FDG uptake and event-free survival in patients in whom DTC was detected by [18F]FDG PET/CT [46]. They concluded that the intense [18F]FDG uptake of the primary DTC was associated with the persistence/progression of disease; however, no further prognostic information could be added when all other prognostic factors had been considered [46]. Analysis of imaging by textural features, also known as radiomics, has emerged as an interesting field of research in the past few years. It allows the characterization of the tumor phenotype, which may be achieved by quantitative measurements, each of which is designed to “capture” specific characteristics of an image [47]. Radiomics implies the extraction of features to characterize a volume of interest (VOI) in the images. These features can be categorized into (1) histogram-based features, (2) texture-based features, (3) edge features, and (4) shape features [48]. Gherghe et al. performed a systematic review of the literature on the use of radiomics analysis to discriminate malignant from benign [18F]FDG-avid thyroid incidentaloma and demonstrated that the use of PET volumetric parameters and radiomics analysis showed great prospects in the diagnosis and stratification of patients with malignant thyroid nodules [48].

3.3. Prostate-Specific Membrane Antigen-Targeting Radiopharmaceuticals

Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein, expressed not only in prostate cancer but also in the endothelium of tumor-associated neovascular malignancies such as head and neck, breast, bladder, lung, gastric, colorectal, and gynecologic cancers [49]. PSMA-targeting radiopharmaceuticals are typically labeled with Gallium-68 (68Ga), such as [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA-617, and [68Ga]Ga-PSMA I&T, and 18F, such as [18F]DCFPyL and [18F]PSMA-1007 [50,51].
68Ga is mainly produced by germanium-68/gallium-68 generator and has a half-life of 68 min. It decays 87.94% through positron emission, with a maximum energy of 1.9 MeV, higher than 18F, inherently leading to a lower resolution [51]. In December 2020, [68Ga]Ga-PSMA-11, also known as [68Ga]Ga-PSMA-HBED-CC, was the first 68Ga-labeled radiopharmaceutical approved by the United States Food and Drug Administration (USFDA) for the PET imaging of PSMA-positive prostate cancer [52]. PSMA-11 was developed to enhance the interaction with the PSMA binding site by the initial linking of the acyclic chelator HBED-CC (N,N′-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N′-diacetic acid) with the aliphatic spacer 6-aminohexanoic acid (Ahx) and later conjugating with a urea-based PSMA inhibitor to form Glu-NH-CO-NH-Lys(Ahx)-HBED-CC. Radiolabeling was performed by adding 68Ga(III) to PSMA-11 [52,53].
Subsequently, [18F]DCFPyL, 2-(3-(1-carboxy-5-[(6-[18F]fluoropyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid was also approved by the USFDA for the detection of possible early metastatic prostate cancer involvement. It is a second-generation 18F-labeled PSMA-targeting tracer and has high tumor:background ratios [54].
PSMA was found to be frequently expressed in the microvessels of thyroid tumors but not in benign thyroid tissue. There was heterogeneous PSMA expression in neovasculature ranging from 19% in benign tumors to over 50% in thyroid cancer, and PSMA expression in cancer was significantly higher than that of benign tumors [55]. Ciappuccini et al. examined PSMA expression using immunohistochemistry in 44 DTC patients with neck persistent/recurrent disease [49]. Around 68% of the patients had at least one PSMA-positive lesion, with a similar proportion in RAI-positive and RAI-negative patients. In RAI-negative patients, higher PSMA expression was found in [18F]FDG-positive than in [18F]FDG-negative patients. Moreover, patients with age ≥ 55 years, primary tumor > 4 cm, or an aggressive subtype had higher PSMA expression, and very high expression was associated with poorer progression-free survival [49]. These findings may lead to new perspectives for the imaging and treatment of DTC, especially in RAI-refractory patients, using PSMA radiopharmaceuticals.
PSMA uptake in DTC on PET/CT imaging has been illustrated [56,57,58,59], as shown in Figure 4.
Metastatic lesions in RAI-refractory DTC patients were demonstrated by PET/CT using 68Ga-based PSMA, which found additional metastatic lesions compared with [18F]FDG [60,61,62]. Vries et al. treated two RAI-refractory DTC patients with [177Lu]Lu-PSMA-617. One showed a modest, temporary response for seven months, while the other experienced disease progression one month after the therapy [62]. The clinical benefits of this therapy in patients with RAI-refractory DTC should be explored.

3.4. Somatostatin Receptor-Targeting Radiopharmaceuticals

A radiolabeled somatostatin analog is applicable for imaging tumors with high expression of somatostatin receptor (SSTR), mainly in neuroendocrine tumors (NETs). Currently, radiopharmaceuticals for the PET imaging of SSTR-positive tumors are commonly labeled with 68Ga: [68Ga]Ga-DOTA-Tyr3-octreotate ([68Ga]Ga-DOTA-TATE); [68Ga]Ga-DOTA-NaI3-octreotide ([68Ga]Ga-DOTA-NOC); and [68Ga]Ga-DOTA-Tyr3-octreotide ([68Ga]Ga-DOTA-TOC). A macrocyclic bifunctional chelator, DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), contains four donor amine nitrogen atoms and four pendant carboxylic acids. It can conjugate small molecules such as somatostatin analogs. DOTA is most commonly used to chelate a wide range of radiometals in various oxidation states, such as Cu(II), In(III), Lu(III), and Ga(III); as a result, stable complexes are formed [63]. The somatostatin analogs exhibit different binding affinities; consequently, the 68Ga-labeled somatostatin analogs bind to different SSTR subtypes. [68Ga]Ga-DOTA-TATE has the highest affinity towards and selectively binds to SSTR type 2. [68Ga]Ga-DOTA-NOC binds to SSTR types 2 and 3, while [68Ga]Ga-DOTA-TOC binds to types 2 and 5 [64].
DTC cells show high expression of SSTR types 2, 3, and 5 [65,66]. Therefore, PET/CT imaging with 68Ga-labeled somatostatin analogs can possibly detect recurrent or metastatic DTC lesions, especially in patients with RAI-refractory status. In a study, there was a different number and intensity of detected lesions among 68Ga-labeled somatostatin analogs. PET/CT imaging with [68Ga]Ga-DOTA-TATE found more lesions than with [68Ga]Ga-DOTA-NOC and higher lesion uptake in DTC patients with elevated serum Tg and negative post-therapeutic 131I scan [67].
Peptide receptor radionuclide therapy (PRRT) using a Lutetium-177 (177Lu)- or Yttrium-90 (90Y)-labeled somatostatin analog compound is indicated for patients with positive SSTR type 2 expression or metastatic or inoperable NETs [68]. In 2018, [177Lu]Lu-DOTA-TATE (Lutathera®) was approved by the USFDA for the treatment of positive gastroenteropancreatic NETs. It significantly improved the progression-free survival and response rate among patients with advanced midgut NETs [69]. A meta-analysis study evaluated the therapeutic effect of PRRT in 67 RAI-refractory DTC patients and reported pooled proportions of objective response rate of 15.61%, disease control rate of 53.95%, and serious adverse events of 2.83%. Moreover, PRRT with 177Lu had a relatively better therapeutic effect than PRRT with 90Y [70]. PRRT may become an alternative treatment for recurrent or metastatic RAI-refractory DTC patients with adequate SSTR expression.

3.5. Fibroblast Activation Protein-Targeting Radiopharmaceuticals

Fibroblast activation protein (FAP) is highly expressed in the stroma of several tumor entities. In particular, breast, colonic, and pancreatic carcinomas are characterized by a strong desmoplastic reaction [71].
The FAP expression is generally very low in normal fibroblasts in the human body. In contrast, cancer-associated fibroblasts are distinctively characterized by the overexpression of FAP, having both exopeptidase and endopeptidase activity [71]. Together with extracellular fibrosis, they contribute up to 90% of the gross tumor mass, leaving tumor cells in the minority [71,72]. Therefore, fibroblast activation protein inhibitors (FAPIs) were developed as an anticancer drug and consecutively advanced into tumor-targeting radiopharmaceuticals [72]. A small-molecule inhibitor (UAMC-1110) based on (4-quinoinolyl)glycinyl-2-cyanopyrrolidine scaffold was found to be a highly selective and potent inhibitor of FAP. Various FAPI tracers are 6-quinolyl-modified derivatives of UAMC-1110, such as FAPI-04, FAPI-46, and FAPI-74 [73]. FAPIs linked to 68Ga via DOTA chelators are mainly FAPI-04, FAPI-46, FAPI-74, DOTA-2P(FAPI)2, DOTA.SA.FAPI, and DATA5m.SA.FAPI [74].
In comparison to [18F]FDG, the current standard oncologic PET, the background uptake of 68Ga-FAPI tracers in the brain, liver, and oral/pharyngeal mucosa was found to be significantly lower; tumor uptake was not statistically different [71].
The average SUVmax of [68Ga]Ga-DOTA-FAPI-04 PET/CT varies among cancers; of those in DTCs, it is not high—the average SUVmax < 6 [72]. A recent prospective clinical trial compared the clinical utility of [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG PET/CT in 35 metastatic DTC patients and reported significantly higher sensitivity of [68Ga]Ga-DOTA-FAPI-04 than [18F]FDG for depicting neck lesions (83% vs 65%) and distant metastases (79% vs. 59%) [75]. Chen et al. analyzed [68Ga]Ga-DOTA-FAPI-04 PET/CT imaging data of 24 RAI-refractory DTC patients and found that 87.5% of the patients had positive metastatic lesions, with a mean SUVmax of 4.25 [76]. In some cases, 68Ga-labeled FAPI showed better detection of metastatic RAI-DTC lesions compared to [18F]FDG, owing to the better signal-to-background ratio [77,78].
For therapeutic purposes, Ballal et al. treated 15 metastatic RAI-refractory DTC patients who progressed on sorafenib/lenvatinib and had moderate-to-excellent uptake of [68Ga]Ga-DOTA.SA.FAPi, with [177Lu]Lu-DOTAGA.(SA.FAPi)2. After the treatment, the serum Tg level significantly decreased. Although none of the patients had a complete molecular response, four had a partial response and three had stable disease [79].

4. Conclusions

Different PET radiopharmaceuticals have been used for the PET/CT imaging of DTC. 124I and [18F]TFB are taken up by DTC via NIS. In RAI-refractory disease, the role of [18F]FDG PET/CT imaging is well established for metastatic detection, while PSMA, SSTR, and FAP-targeting radiopharmaceuticals are applicable for both imaging and therapy.

Author Contributions

Conceptualization, W.C.; methodology, W.C.; investigation, C.S.; resources, W.C.; writing—original draft preparation, C.S.; writing—review and editing, C.S., P.C. and W.C.; visualization, C.S. and W.C.; supervision, W.C.; project administration, W.C. All authors have read and agreed to the published version of the manuscript.

Funding

This review article received no external funding and the APC was funded by the Faculty of Medicine, Ramathibodi Hospital, Mahidol University.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this review article.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Haugen, B.R.; Alexander, E.K.; Bible, K.C.; Doherty, G.M.; Mandel, S.J.; Nikiforov, Y.E.; Pacini, F.; Randolph, G.W.; Sawka, A.M.; Schlumberger, M.; et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016, 26, 1–133. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Dunlap, Q.; Davies, L. Differentiated Thyroid Cancer Incidence. In Surgery of the Thyroid and Parathyroid Glands; Elsevier: Amsterdam, The Netherlands, 2021; pp. 174–180.e2. ISBN 978-0-323-66127-0. [Google Scholar]
  3. Seib, C.D.; Sosa, J.A. Evolving Understanding of the Epidemiology of Thyroid Cancer. Endocrinol. Metab. Clin. N. Am. 2019, 48, 23–35. [Google Scholar] [CrossRef] [PubMed]
  4. SEER*Explorer Surveillance Research Program, National Cancer Institute. Available online: https://seer.cancer.gov/statistics-network/explorer/application.html (accessed on 11 June 2022).
  5. O’Malley, J.P.; Ziessman, H.A. Nuclear Medicine and Molecular Imaging: The Requisites, 5th ed.; Elsevier Inc: St. Louis, MO, USA, 2019; ISBN 978-0-323-53037-8. [Google Scholar]
  6. Glazer, D.I.; Brown, R.K.J.; Wong, K.K.; Savas, H.; Gross, M.D.; Avram, A.M. SPECT/CT Evaluation of Unusual Physiologic Radioiodine Biodistributions: Pearls and Pitfalls in Image Interpretation. RadioGraphics 2013, 33, 397–418. [Google Scholar] [CrossRef]
  7. Cascini, G.L.; Niccoli Asabella, A.; Notaristefano, A.; Restuccia, A.; Ferrari, C.; Rubini, D.; Altini, C.; Rubini, G. 124Iodine: A Longer-Life Positron Emitter Isotope—New Opportunities in Molecular Imaging. BioMed Res. Int. 2014, 2014, 672094. [Google Scholar] [CrossRef] [Green Version]
  8. Mahajan, S.; Divgi, C.R. The Role of Iodine-124 Positron Emission Tomography in Molecular Imaging. Clin. Transl. Imaging 2016, 4, 297–306. [Google Scholar] [CrossRef]
  9. Zampella, E.; Klain, M.; Pace, L.; Cuocolo, A. PET/CT in the Management of Differentiated Thyroid Cancer. Diagn. Interv. Imaging 2021, 102, 515–523. [Google Scholar] [CrossRef] [PubMed]
  10. Avram, A.M.; Giovanella, L.; Greenspan, B.; Lawson, S.A.; Luster, M.; Van Nostrand, D.; Peacock, J.G.; Ovčariček, P.P.; Silberstein, E.; Tulchinsky, M.; et al. SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version. J. Nucl. Med. 2022, 63, 15N–35N. [Google Scholar]
  11. Klain, M.; Zampella, E.; Nappi, C.; Nicolai, E.; Ambrosio, R.; Califaretti, E.; Lamartina, L.; Schlumberger, M.; Deandreis, D.; Salvatore, D.; et al. Advances in Functional Imaging of Differentiated Thyroid Cancer. Cancers 2021, 13, 4748. [Google Scholar] [CrossRef] [PubMed]
  12. Wu, D.; Plyku, D.; Kulkarni, K.; Garcia, C.; Atkins, F.; Tefera, E.; Burman, K.D.; Wartofsky, L.; Van Nostrand, D. Optimal Time for 124I PET/CT Imaging in Metastatic Differentiated Thyroid Cancer. Clin. Nucl. Med. 2021, 46, 283–288. [Google Scholar] [CrossRef]
  13. Ruhlmann, M.; Jentzen, W.; Ruhlmann, V.; Pettinato, C.; Rossi, G.; Binse, I.; Bockisch, A.; Rosenbaum-Krumme, S. High Level of Agreement between Pretherapeutic 124I PET and Intratherapeutic 131I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases. J. Nucl. Med. 2016, 57, 1339–1342. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Van Nostrand, D.; Moreau, S.; Bandaru, V.V.; Atkins, F.; Chennupati, S.; Mete, M.; Burman, K.; Wartofsky, L. 124I Positron Emission Tomography Versus 131I Planar Imaging in the Identification of Residual Thyroid Tissue and/or Metastasis in Patients Who Have Well-Differentiated Thyroid Cancer. Thyroid 2010, 20, 879–883. [Google Scholar] [CrossRef] [PubMed]
  15. Khorjekar, G.R.; Van Nostrand, D.; Garcia, C.; O’Neil, J.; Moreau, S.; Atkins, F.B.; Mete, M.; Orquiza, M.H.; Burman, K.; Wartofsky, L. Do Negative 124I Pretherapy Positron Emission Tomography Scans in Patients with Elevated Serum Thyroglobulin Levels Predict Negative 131I Posttherapy Scans? Thyroid 2014, 24, 1394–1399. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Phan, H.T.T.; Jager, P.L.; Paans, A.M.J.; Plukker, J.T.M.; Sturkenboom, M.G.G.; Sluiter, W.J.; Wolffenbuttel, B.H.R.; Dierckx, R.A.J.O.; Links, T.P. The Diagnostic Value of 124I-PET in Patients with Differentiated Thyroid Cancer. Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 958–965. [Google Scholar] [CrossRef] [Green Version]
  17. Capoccetti, F.; Criscuoli, B.; Rossi, G.; Ferretti, F.; Manni, C.; Brianzoni, E. The Effectiveness of 124I PET/CT in Patients with Differentiated Thyroid Cancer. Q. J. Nucl. Med. Mol. Imaging 2009, 53, 536–545. [Google Scholar]
  18. De Pont, C.; Halders, S.; Bucerius, J.; Mottaghy, F.; Brans, B. 124I PET/CT in the Pretherapeutic Staging of Differentiated Thyroid Carcinoma: Comparison with Posttherapy 131I SPECT/CT. Eur. J. Nucl. Med. Mol. Imaging 2013, 40, 693–700. [Google Scholar] [CrossRef]
  19. Gulec, S.A.; Kuker, R.A.; Goryawala, M.; Fernandez, C.; Perez, R.; Khan-Ghany, A.; Apaza, A.; Harja, E.; Harrell, M. 124I PET/CT in Patients with Differentiated Thyroid Cancer: Clinical and Quantitative Image Analysis. Thyroid 2016, 26, 441–448. [Google Scholar] [CrossRef]
  20. Kist, J.W.; de Keizer, B.; van der Vlies, M.; Brouwers, A.H.; Huysmans, D.A.; van der Zant, F.M.; Hermsen, R.; Stokkel, M.P.M.; Hoekstra, O.S.; Vogel, W.V. 124I PET/CT to Predict the Outcome of Blind 131I Treatment in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET). J. Nucl. Med. 2016, 57, 701–707. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  21. Wong, B.Z.Y.; Dickie, G.; Garcia, P.; Scott, D.; Pattison, D.A. 124I-PET/CT–Guided Diagnosis and Personalized Treatment of Metastatic Papillary Thyroid Cancer to the Pancreas. Clin. Nucl. Med. 2021, 46, 337–339. [Google Scholar] [CrossRef] [PubMed]
  22. Weber, M.; Binse, I.; Nagarajah, J.; Bockisch, A.; Herrmann, K.; Jentzen, W. The Role of 124I PET/CT Lesion Dosimetry in Differentiated Thyroid Cancer. Q. J. Nucl. Med. Mol. Imaging 2019, 63, 235–252. [Google Scholar] [CrossRef] [PubMed]
  23. Santhanam, P.; Taieb, D.; Solnes, L.; Marashdeh, W.; Ladenson, P.W. Utility of I-124 PET/CT in Identifying Radioiodine Avid Lesions in Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis. Clin. Endocrinol. 2017, 86, 645–651. [Google Scholar] [CrossRef] [Green Version]
  24. Jacobson, O.; Kiesewetter, D.O.; Chen, X. Fluorine-18 Radiochemistry, Labeling Strategies and Synthetic Routes. Bioconjug. Chem. 2015, 26, 1–18. [Google Scholar] [CrossRef]
  25. O’Doherty, J.; Jauregui-Osoro, M.; Brothwood, T.; Szyszko, T.; Marsden, P.K.; O’Doherty, M.J.; Cook, G.J.R.; Blower, P.J.; Lewington, V. 18F-Tetrafluoroborate, a PET Probe for Imaging Sodium/Iodide Symporter Expression: Whole-Body Biodistribution, Safety, and Radiation Dosimetry in Thyroid Cancer Patients. J. Nucl. Med. 2017, 58, 1666–1671. [Google Scholar] [CrossRef] [Green Version]
  26. Khoshnevisan, A.; Jauregui-Osoro, M.; Shaw, K.; Torres, J.B.; Young, J.D.; Ramakrishnan, N.K.; Jackson, A.; Smith, G.E.; Gee, A.D.; Blower, P.J. [18F]Tetrafluoroborate as a PET Tracer for the Sodium/Iodide Symporter: The Importance of Specific Activity. EJNMMI Res. 2016, 6, 34. [Google Scholar] [CrossRef] [Green Version]
  27. Dittmann, M.; Gonzalez Carvalho, J.M.; Rahbar, K.; Schäfers, M.; Claesener, M.; Riemann, B.; Seifert, R. Incremental Diagnostic Value of [18F]Tetrafluoroborate PET-CT Compared to [131I]Iodine Scintigraphy in Recurrent Differentiated Thyroid Cancer. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 2639–2646. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Samnick, S.; Al-Momani, E.; Schmid, J.-S.; Mottok, A.; Buck, A.K.; Lapa, C. Initial Clinical Investigation of [18F]Tetrafluoroborate PET/CT in Comparison to [124I]Iodine PET/CT for Imaging Thyroid Cancer. Clin. Nucl. Med. 2018, 43, 162–167. [Google Scholar] [CrossRef]
  29. Yu, S. Review of 18F-FDG Synthesis and Quality Control. Biomed. Imaging Interv. J. 2006, 2, e57. [Google Scholar] [CrossRef]
  30. Pauwels, E.K.J.; Coumou, A.W.; Kostkiewicz, M.; Kairemo, K. [18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Imaging in Oncology: Initial Staging and Evaluation of Cancer Therapy. Med. Princ. Pract. 2013, 22, 427–437. [Google Scholar] [CrossRef]
  31. Kapoor, V.; McCook, B.M.; Torok, F.S. An Introduction to PET-CT Imaging. RadioGraphics 2004, 24, 523–543. [Google Scholar] [CrossRef]
  32. Feine, U.; Lietzenmayer, R.; Hanke, J.P.; Held, J.; Wöhrle, H.; Müller-Schauenburg, W. Fluorine-18-FDG and Iodine-131-Iodide Uptake in Thyroid Cancer. J. Nucl. Med. 1996, 37, 1468–1472. [Google Scholar]
  33. Bongiovanni, M.; Paone, G.; Ceriani, L.; Pusztaszeri, M. Cellular and Molecular Basis for Thyroid Cancer Imaging in Nuclear Medicine. Clin. Transl. Imaging 2013, 1, 149–161. [Google Scholar] [CrossRef] [Green Version]
  34. Heydarzadeh, S.; Moshtaghie, A.A.; Daneshpoor, M.; Hedayati, M. Regulators of Glucose Uptake in Thyroid Cancer Cell Lines. Cell Commun. Signal. 2020, 18, 83. [Google Scholar] [CrossRef]
  35. Abelleira, E.; García Falcone, M.G.; Bueno, F.; Pitoia, F. Role of 18F-FDG-PET/CT in Patients with Differentiated Thyroid Cancer with Biochemical Incomplete or Indeterminate Response to Treatment. Endocrinol. Diabetes Nutr. 2020, 67, 517–524. [Google Scholar] [CrossRef]
  36. Qichang, W.; Lin, B.; Gege, Z.; Youjia, Z.; Qingjie, M.; Renjie, W.; Bin, J. Diagnostic Performance of 18F-FDG-PET/CT in DTC Patients with Thyroglobulin Elevation and Negative Iodine Scintigraphy: A Meta-Analysis. Eur. J. Endocrinol. 2019, 181, 93–102. [Google Scholar] [CrossRef]
  37. Caetano, R.; Bastos, C.R.G.; de Oliveira, I.A.G.; da Silva, R.M.; Fortes, C.P.D.D.; Pepe, V.L.E.; Reis, L.G.; Braga, J.U. Accuracy of Positron Emission Tomography and Positron Emission Tomography-CT in the Detection of Differentiated Thyroid Cancer Recurrence with Negative 131I Whole-Body Scan Results: A Meta-Analysis: PET and PET-CT in the Detection of Recurrent Differentiated Thyroid Cancer. Head Neck 2016, 38, 316–327. [Google Scholar] [CrossRef]
  38. Vrachimis, A.; Burg, M.C.; Wenning, C.; Allkemper, T.; Weckesser, M.; Schäfers, M.; Stegger, L. [18F]FDG PET/CT Outperforms [18F]FDG PET/MRI in Differentiated Thyroid Cancer. Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 212–220. [Google Scholar] [CrossRef]
  39. Wang, H.; Dai, H.; Li, Q.; Shen, G.; Shi, L.; Tian, R. Investigating 18F-FDG PET/CT Parameters as Prognostic Markers for Differentiated Thyroid Cancer: A Systematic Review. Front. Oncol. 2021, 11, 648658. [Google Scholar] [CrossRef]
  40. Albano, D.; Dondi, F.; Mazzoletti, A.; Bellini, P.; Rodella, C.; Bertagna, F. Prognostic Role of 2-[18F]FDG PET/CT Metabolic Volume Parameters in Patients Affected by Differentiated Thyroid Carcinoma with High Thyroglobulin Level, Negative 131I WBS and Positive 2-[18F]-FDG PET/CT. Diagnostics 2021, 11, 2189. [Google Scholar] [CrossRef] [PubMed]
  41. Liu, Y. The Role of 18F-FDG PET/CT in the Follow-up of Well-Differentiated Thyroid Cancer with Negative Thyroglobulin but Positive and/or Elevated Antithyroglobulin Antibody. Nucl. Med. Commun. 2016, 37, 577–582. [Google Scholar] [CrossRef]
  42. Kim, S.-J.; Lee, S.-W.; Pak, K.; Shim, S.-R. Diagnostic Performance of PET in Thyroid Cancer with Elevated Anti-Tg Ab. Endocr.-Relat. Cancer 2018, 25, 643–652. [Google Scholar] [CrossRef]
  43. Ozkan, E.; Aras, G.; Kucuk, N.O. Correlation of 18F-FDG PET/CT Findings with Histopathological Results in Differentiated Thyroid Cancer Patients Who Have Increased Thyroglobulin or Antithyroglobulin Antibody Levels and Negative 131I Whole-Body Scan Results. Clin. Nucl. Med. 2013, 38, 326–331. [Google Scholar] [CrossRef]
  44. Ozkan, E.; Soydal, C.; Araz, M.; Aras, G.; Ibis, E. The Additive Clinical Value of 18F-FDG PET/CT in Defining the Recurrence of Disease in Patients with Differentiated Thyroid Cancer Who Have Isolated Increased Antithyroglobulin Antibody Levels. Clin. Nucl. Med. 2012, 37, 755–758. [Google Scholar] [CrossRef] [PubMed]
  45. de Leijer, J.F.; Metman, M.J.H.; van der Hoorn, A.; Brouwers, A.H.; Kruijff, S.; van Hemel, B.M.; Links, T.P.; Westerlaan, H.E. Focal Thyroid Incidentalomas on 18F-FDG PET/CT: A Systematic Review and Meta-Analysis on Prevalence, Risk of Malignancy and Inconclusive Fine Needle Aspiration. Front. Endocrinol. 2021, 12, 723394. [Google Scholar] [CrossRef] [PubMed]
  46. Piccardo, A.; Puntoni, M.; Bertagna, F.; Treglia, G.; Foppiani, L.; Arecco, F.; Giubbini, R.; Naseri, M.; Cistaro, A.; Cabria, M.; et al. 18F-FDG Uptake as a Prognostic Variable in Primary Differentiated Thyroid Cancer Incidentally Detected by PET/CT: A Multicentre Study. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 1482–1491. [Google Scholar] [CrossRef]
  47. Presotto, L.; Bettinardi, V.; De Bernardi, E.; Belli, M.L.; Cattaneo, G.M.; Broggi, S.; Fiorino, C. PET Textural Features Stability and Pattern Discrimination Power for Radiomics Analysis: An “Ad-Hoc” Phantoms Study. Phys. Med. 2018, 50, 66–74. [Google Scholar] [CrossRef] [PubMed]
  48. Gherghe, M.; Lazar, A.M.; Mutuleanu, M.-D.; Stanciu, A.E.; Martin, S. Radiomics Analysis of [18F]FDG PET/CT Thyroid Incidentalomas: How Can It Improve Patients’ Clinical Management? A Systematic Review from the Literature. Diagnostics 2022, 12, 471. [Google Scholar] [CrossRef] [PubMed]
  49. Ciappuccini, R.; Saguet-Rysanek, V.; Giffard, F.; Licaj, I.; Dorbeau, M.; Clarisse, B.; Poulain, L.; Bardet, S. PSMA Expression in Differentiated Thyroid Cancer: Association with Radioiodine, 18FDG Uptake, and Patient Outcome. J. Clin. Endocrinol. Metab. 2021, 106, 3536–3545. [Google Scholar] [CrossRef]
  50. Lawhn-Heath, C.; Salavati, A.; Behr, S.C.; Rowe, S.P.; Calais, J.; Fendler, W.P.; Eiber, M.; Emmett, L.; Hofman, M.S.; Hope, T.A. Prostate-Specific Membrane Antigen PET in Prostate Cancer. Radiology 2021, 299, 248–260. [Google Scholar] [CrossRef] [PubMed]
  51. Martiniova, L.; De Palatis, L.; Etchebehere, E.; Ravizzini, G. Gallium-68 in Medical Imaging. Curr. Radiopharm. 2016, 9, 187–207. [Google Scholar] [CrossRef] [PubMed]
  52. Hennrich, U.; Eder, M. [68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer. Pharmaceuticals 2021, 14, 713. [Google Scholar] [CrossRef] [PubMed]
  53. Gourni, E.; Henriksen, G. Metal-Based PSMA Radioligands. Molecules 2017, 22, 523. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Basuli, F.; Phelps, T.E.; Zhang, X.; Woodroofe, C.C.; Roy, J.; Choyke, P.L.; Swenson, R.E.; Jagoda, E.M. Fluorine-18 Labeled Urea-Based Ligands Targeting Prostate-Specific Membrane Antigen (PSMA) with Increased Tumor and Decreased Renal Uptake. Pharmaceuticals 2022, 15, 597. [Google Scholar] [CrossRef] [PubMed]
  55. Bychkov, A.; Vutrapongwatana, U.; Tepmongkol, S.; Keelawat, S. PSMA Expression by Microvasculature of Thyroid Tumors—Potential Implications for PSMA Theranostics. Sci. Rep. 2017, 7, 5202. [Google Scholar] [CrossRef] [PubMed]
  56. Usmani, S.; Al-Turkait, D.; Al-Kandari, F.; Ahmed, N. Thyroid Cancer Detected on 68Ga-PMSA PET/CT. J. Pak. Med. Assoc. 2021, 71, 1511–1512. [Google Scholar] [PubMed]
  57. Singh, D.; Horneman, R.; Nagra, N.K. More than the Prostate: Intrapancreatic Accessory Spleen and Papillary Thyroid Cancer Detected with 18F-PSMA PET/CT. Hell. J. Nucl. Med. 2018, 21, 145–147. [Google Scholar] [CrossRef]
  58. Lawhn-Heath, C.; Yom, S.S.; Liu, C.; Villanueva-Meyer, J.E.; Aslam, M.; Smith, R.; Narwal, M.; Juarez, R.; Behr, S.C.; Pampaloni, M.H.; et al. Gallium-68 Prostate-Specific Membrane Antigen ([68Ga]Ga-PSMA-11) PET for Imaging of Thyroid Cancer: A Feasibility Study. EJNMMI Res. 2020, 10, 128. [Google Scholar] [CrossRef]
  59. Pitalua-Cortes, Q.; García-Perez, F.O.; Vargas-Ahumada, J.; Gonzalez-Rueda, S.; Gomez-Argumosa, E.; Ignacio-Alvarez, E.; Soldevilla-Gallardo, I.; Torres-Agredo, L. Head-to-Head Comparison of 68Ga-PSMA-11 and 131I in the Follow-Up of Well-Differentiated Metastatic Thyroid Cancer: A New Potential Theragnostic Agent. Front. Endocrinol. 2021, 12, 794759. [Google Scholar] [CrossRef] [PubMed]
  60. Alçın, G.; Arslan, E.; Aksoy, T.; Çermik, T.F. 68Ga-PSMA Uptake in a Radioiodine-Refractory Metastatic Differentiated Thyroid Cancer Patient. Rev. Esp. Med. Nucl. Imagen Mol. 2021, 41, S42–S43. [Google Scholar] [CrossRef]
  61. Verma, P.; Malhotra, G.; Meshram, V.; Chandak, A.; Sonavane, S.; Lila, A.R.; Bandgar, T.R.; Asopa, R.V. Prostate-Specific Membrane Antigen Expression in Patients with Differentiated Thyroid Cancer with Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET/CT. Clin. Nucl. Med. 2021, 46, e406–e409. [Google Scholar] [CrossRef]
  62. De Vries, L.H.; Lodewijk, L.; Braat, A.J.A.T.; Krijger, G.C.; Valk, G.D.; Lam, M.G.E.H.; Borel Rinkes, I.H.M.; Vriens, M.R.; de Keizer, B. 68Ga-PSMA PET/CT in Radioactive Iodine-Refractory Differentiated Thyroid Cancer and First Treatment Results with 177Lu-PSMA-617. EJNMMI Res. 2020, 10, 18. [Google Scholar] [CrossRef]
  63. Lewis, J.S.; Windhorst, A.D.; Zeglis, B.M. (Eds.) Radiopharmaceutical Chemistry; Springer International Publishing: Cham, Switzerland, 2019; ISBN 978-3-319-98946-4. [Google Scholar]
  64. Johnbeck, C.B.; Knigge, U.; Kjær, A. PET Tracers for Somatostatin Receptor Imaging of Neuroendocrine Tumors: Current Status and Review of the Literature. Future Oncol. 2014, 10, 2259–2277. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Klagge, A.; Krause, K.; Schierle, K.; Steinert, F.; Dralle, H.; Fuhrer, D. Somatostatin Receptor Subtype Expression in Human Thyroid Tumours. Horm. Metab. Res. 2010, 42, 237–240. [Google Scholar] [CrossRef] [PubMed]
  66. Pazaitou-Panayiotou, K.; Tiensuu Janson, E.; Koletsa, T.; Kotoula, V.; Stridsberg, M.; Karkavelas, G.; Karayannopoulou, G. Somatostatin Receptor Expression in Non-Medullary Thyroid Carcinomas. Hormones 2012, 11, 290–296. [Google Scholar] [CrossRef]
  67. Ocak, M.; Demirci, E.; Kabasakal, L.; Aygun, A.; Tutar, R.O.; Araman, A.; Kanmaz, B. Evaluation and Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT Imaging in Well-Differentiated Thyroid Cancer. Nucl. Med. Commun. 2013, 34, 1084–1089. [Google Scholar] [CrossRef] [PubMed]
  68. Bodei, L.; Mueller-Brand, J.; Baum, R.P.; Pavel, M.E.; Hörsch, D.; O’Dorisio, M.S.; O’Dorisio, T.M.; Howe, J.R.; Cremonesi, M.; Kwekkeboom, D.J.; et al. Erratum to: The Joint IAEA, EANM, and SNMMI Practical Guidance on Peptide Receptor Radionuclide Therapy (PRRNT) in Neuroendocrine Tumours. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 584. [Google Scholar] [CrossRef]
  69. Strosberg, J.; El-Haddad, G.; Wolin, E.; Hendifar, A.; Yao, J.; Chasen, B.; Mittra, E.; Kunz, P.L.; Kulke, M.H.; Jacene, H.; et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N. Engl. J. Med. 2017, 376, 125–135. [Google Scholar] [CrossRef] [PubMed]
  70. Lee, D.Y.; Kim, Y. Peptide Receptor Radionuclide Therapy in Patients with Differentiated Thyroid Cancer: A Meta-Analysis. Clin. Nucl. Med. 2020, 45, 604–610. [Google Scholar] [CrossRef] [PubMed]
  71. Giesel, F.L.; Kratochwil, C.; Lindner, T.; Marschalek, M.M.; Loktev, A.; Lehnert, W.; Debus, J.; Jäger, D.; Flechsig, P.; Altmann, A.; et al. 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. J. Nucl. Med. 2019, 60, 386–392. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Kratochwil, C.; Flechsig, P.; Lindner, T.; Abderrahim, L.; Altmann, A.; Mier, W.; Adeberg, S.; Rathke, H.; Röhrich, M.; Winter, H.; et al. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J. Nucl. Med. 2019, 60, 801–805. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  73. Lindner, T.; Giesel, F.L.; Kratochwil, C.; Serfling, S.E. Radioligands Targeting Fibroblast Activation Protein (FAP). Cancers 2021, 13, 5744. [Google Scholar] [CrossRef] [PubMed]
  74. Huang, R.; Pu, Y.; Huang, S.; Yang, C.; Yang, F.; Pu, Y.; Li, J.; Chen, L.; Huang, Y. FAPI-PET/CT in Cancer Imaging: A Potential Novel Molecule of the Century. Front. Oncol. 2022, 12, 854658. [Google Scholar] [CrossRef] [PubMed]
  75. Fu, H.; Wu, J.; Huang, J.; Sun, L.; Wu, H.; Guo, W.; Qiu, S.; Chen, H. 68Ga Fibroblast Activation Protein Inhibitor PET/CT in the Detection of Metastatic Thyroid Cancer: Comparison with 18F-FDG PET/CT. Radiology 2022, 304, 212430. [Google Scholar] [CrossRef] [PubMed]
  76. Chen, Y.; Zheng, S.; Zhang, J.; Yao, S.; Miao, W. 68Ga-DOTA-FAPI-04 PET/CT Imaging in Radioiodine-Refractory Differentiated Thyroid Cancer (RR-DTC) Patients. Ann. Nucl. Med. 2022, 36, 610–622. [Google Scholar] [CrossRef] [PubMed]
  77. Wu, J.; Ou, L.; Zhang, C. Comparison of 68Ga-FAPI and 18F-FDG PET/CT in Metastases of Papillary Thyroid Carcinoma. Endocrine 2021, 73, 767–768. [Google Scholar] [CrossRef] [PubMed]
  78. Fu, H.; Fu, J.; Huang, J.; Pang, Y.; Chen, H. 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT for Detecting Metastatic Lesions in a Case of Radioiodine-Refractory Differentiated Thyroid Cancer. Clin. Nucl. Med. 2021, 46, 940–942. [Google Scholar] [CrossRef] [PubMed]
  79. Ballal, S.; Yadav, M.P.; Moon, E.S.; Roesch, F.; Kumari, S.; Agarwal, S.; Tripathi, M.; Sahoo, R.K.; Mangu, B.S.; Tupalli, A.; et al. Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot Study. Thyroid 2021, 32, 65–77. [Google Scholar] [CrossRef] [PubMed]
Molecules 27 04936 g001 550
Figure 1. A 59-year-old woman with PTC with lung and bone metastases. She was initially investigated by [18F]FDG PET/CT due to multiple lung nodules on chest radiograph. [18F]FDG maximum-intensity (MIP) skull-to-mid-thigh PET (A) and axial fused PET/CT (B) images showed non-FDG-avid small lung nodules. Subsequently, wedge resection of the superior segment of the right lower lung lobe revealed metastatic well-differentiated follicular-derived thyroid carcinoma. After total thyroidectomy, the pre-therapeutic (2 mCi) 131I WBS (C), coronal (D), and axial (E) fused SPECT/CT images showed intense iodine uptake in residual thyroid, diffuse lung, and bone metastases. She received 131I therapies (cumulative dose of 600 mCi). (F) The last post-therapeutic 131I WBS image revealed resolution of all iodine-avid lesions, and serum-stimulated Tg declined (<1 ng/mL), implying an excellent response.
Figure 1. A 59-year-old woman with PTC with lung and bone metastases. She was initially investigated by [18F]FDG PET/CT due to multiple lung nodules on chest radiograph. [18F]FDG maximum-intensity (MIP) skull-to-mid-thigh PET (A) and axial fused PET/CT (B) images showed non-FDG-avid small lung nodules. Subsequently, wedge resection of the superior segment of the right lower lung lobe revealed metastatic well-differentiated follicular-derived thyroid carcinoma. After total thyroidectomy, the pre-therapeutic (2 mCi) 131I WBS (C), coronal (D), and axial (E) fused SPECT/CT images showed intense iodine uptake in residual thyroid, diffuse lung, and bone metastases. She received 131I therapies (cumulative dose of 600 mCi). (F) The last post-therapeutic 131I WBS image revealed resolution of all iodine-avid lesions, and serum-stimulated Tg declined (<1 ng/mL), implying an excellent response.
Molecules 27 04936 g001
Molecules 27 04936 g002 550
Figure 2. A 70-year-old man with PTC and nodal metastasis was treated with surgery and 131I therapy (cumulative dose of 600 mCi). (A) The last post-therapeutic 131I WBS was negative despite elevated serum Tg. [18F]FDG MIP skull-to-mid-thigh PET (B) and axial fused PET/CT (C–G) images showed [18F]FDG-avid lesions in left retropharyngeal ((C), green arrow), left cervical ((D), red arrow), and right cervical ((E), blue arrow) lymph nodes, and thyroidectomy bed (F,G). All are suggestive of RAI-refractory disease.
Figure 2. A 70-year-old man with PTC and nodal metastasis was treated with surgery and 131I therapy (cumulative dose of 600 mCi). (A) The last post-therapeutic 131I WBS was negative despite elevated serum Tg. [18F]FDG MIP skull-to-mid-thigh PET (B) and axial fused PET/CT (C–G) images showed [18F]FDG-avid lesions in left retropharyngeal ((C), green arrow), left cervical ((D), red arrow), and right cervical ((E), blue arrow) lymph nodes, and thyroidectomy bed (F,G). All are suggestive of RAI-refractory disease.
Molecules 27 04936 g002
Molecules 27 04936 g003 550
Figure 3. [18F]FDG-avid thyroid incidentaloma. (A,B) A 51-year-old woman with uterine cervical cancer on surveillance. [18F]FDG MIP skull-to-mid-thigh PET (A) and axial fused PET/CT (B) images showed focal [18F]FDG uptake in the left thyroid lobe (red arrow). She underwent left thyroid lobectomy and the pathological diagnosis was PTC. (C) A 56-year-old man with a fever of unknown origin. [18F]FDG MIP whole-body PET image revealed diffuse [18F]FDG uptake of the thyroid gland (green arrow). After investigation, he was diagnosed with subacute thyroiditis.
Figure 3. [18F]FDG-avid thyroid incidentaloma. (A,B) A 51-year-old woman with uterine cervical cancer on surveillance. [18F]FDG MIP skull-to-mid-thigh PET (A) and axial fused PET/CT (B) images showed focal [18F]FDG uptake in the left thyroid lobe (red arrow). She underwent left thyroid lobectomy and the pathological diagnosis was PTC. (C) A 56-year-old man with a fever of unknown origin. [18F]FDG MIP whole-body PET image revealed diffuse [18F]FDG uptake of the thyroid gland (green arrow). After investigation, he was diagnosed with subacute thyroiditis.
Molecules 27 04936 g003
Molecules 27 04936 g004 550
Figure 4. A 59-year-old man with prostate cancer post-radical prostatectomy. [68Ga]Ga-PSMA-11 MIP skull-to-mid-thigh PET (A) and axial fused PET/CT (B) images revealed a PSMA-avid right thyroid nodule (red arrow) despite bilateral thyroid nodules. The ultrasound images (C,D) revealed right and left thyroid nodules, respectively. He subsequently underwent thyroid surgery with confirmed PTC in the right thyroid nodule and benign left thyroid nodule.
Figure 4. A 59-year-old man with prostate cancer post-radical prostatectomy. [68Ga]Ga-PSMA-11 MIP skull-to-mid-thigh PET (A) and axial fused PET/CT (B) images revealed a PSMA-avid right thyroid nodule (red arrow) despite bilateral thyroid nodules. The ultrasound images (C,D) revealed right and left thyroid nodules, respectively. He subsequently underwent thyroid surgery with confirmed PTC in the right thyroid nodule and benign left thyroid nodule.
Molecules 27 04936 g004
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Sakulpisuti, C.; Charoenphun, P.; Chamroonrat, W. Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer. Molecules 2022, 27, 4936. https://doi.org/10.3390/molecules27154936

AMA Style

Sakulpisuti C, Charoenphun P, Chamroonrat W. Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer. Molecules. 2022; 27(15):4936. https://doi.org/10.3390/molecules27154936

Chicago/Turabian Style

Sakulpisuti, Chaninart, Putthiporn Charoenphun, and Wichana Chamroonrat. 2022. "Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer" Molecules 27, no. 15: 4936. https://doi.org/10.3390/molecules27154936

APA Style

Sakulpisuti, C., Charoenphun, P., & Chamroonrat, W. (2022). Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer. Molecules, 27(15), 4936. https://doi.org/10.3390/molecules27154936

Article Metrics

Back to TopTop